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including discrimination between the thrombotic and atherosclerotic plaque com-
ponents. We sought to investigate the feasibility of thrombus quantification and its
monitoring in patients with high thrombotic burden acute coronary syndromes.
Methods: Patients with successfully revascularized acute coronary syn-
dromes and a large thrombus burden on initial coronary angiography who ben-
eficiated from repeated TD-OCT examinations in our institution were suitable
for inclusion. Coronary lesion stenosis degree was determined by quantitative
coronary angiography (QCA) methods. Thrombus volume, maximal surface and
minimal luminal area (MLA) were quantified by serial area measurement within
the athero-thrombotic culprit lesion in 1 mm intervals before any stenting.
Results: Eleven patients underwent 2 consecutive TD-OCT examinations.
The OCT image quality was suitable for thrombus quantification in n=9 subjects
(89% men/ age=62.4±5.7y/ 89% STEMI). All patients were under anticoagulant
and dual antiplatelet therapy between the two procedures (mean delay: 4.1±
0.4 days). No adverse events were observed following OCT analysis.
We measured a progressive reduction of thrombus burden between the two
analysis, as assessed by the decrease of thrombus volume (5.3±1.7
vs.11.0±3.4 mm3, p=0.004), length (7.4±1.0 vs. 10.9±1.8 mm, p=0.02) and
increase of MLA (2.5±0.6 mm2 vs. 1.8±0.3 mm2, p=0.02). However, the
degree of stenosis analyzed by QCA didn’t significantly decrease over time
(49.7±4.6% vs. 55.7±6.6%, p= 0.15). The thrombus volume reduction was
time dependent, as witnessed by the high correlation between the percentage
of thrombus volume decrease and the delay between analysis (R=0.87,
p=0.002). The observed thrombus volume reduction rate was evaluated to
12% of the initial volume per day under medical therapy.
Conclusion: TD-OCT assessment of thrombus volume in patients with
ACS is feasible, safe and could allow in vivo clot regression monitoring.
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Background: We report on the management of and processes of care in
consecutive patients with Takotsubo syndrome using data from a French reg-
istry (OFSETT).
Methods: Between November 2010 and December 2011, 15 non-academic
hospitals included consecutive patients diagnosed with Takotsubo syndrome
according to the Mayo clinic diagnostic criteria.
Results: A total of 121 patients were enrolled: 89% were women and the
mean age was 72±12 years. Most of the women (89%) were >50 years’ old; 8%
of patients had diabetes, 30% were current smokers and 52% had hypertension.
Symptoms of Takotsubo syndrome were chest pain (81%), dyspnoea (27%) and/
or syncope (5%). The mean maximum troponin level was 7.8 ng/mL and the
mean maximum B-type natriuretic peptide level was 1013 pg/mL. ECG showed
a negative T wave in 73%, ST elevation in 42% and/or a new Q wave in 29%
of patients. One patient was treated with fibrinolysis. Coronary angiography was
performed in all patients. Coronary arteries were angiographically normal in
78% of patients and showed <50% stenosis in 22%. Left ventricle (LV) angio-
graphy showed apical ballooning in 35% of patients. The mean LV ejection
fraction was 42±13% on echocardiography and 46±10% on angiography. The
target event was identified in 55% of the patients: mental stress in 61% and
physical stress in 29%. In-hospital treatment included nitrates (11% of patients),
unfractionated heparin (25%), low-molecular-weight heparin (79%), aspirin
(91%), antiplatelets (82%), and angiotensin-converting enzyme inhibitors/angio-
tensin receptor inhibitors (ACE/ARB) (75%). None of the patients died during
hospitalization. At discharge, patients were treated with aspirin (59%), statins
(46%), beta-blockers (75%), ACE/ARB (79%) and/or neurotropic agents (26%).
Conclusion: These observational data from 15 non-academic French hos-
pitals provide insights into the characteristics of patients with Takotsubo syn-
drome and current processes of care for this population.
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Objective: To investigate whether elevated triglycerides and low high-den-
sity lipoprotein (HDL) cholesterol (atherogenic dyslipidemia) are predictive of
risk for silent myocardial ischemia (SMI) or angiographic coronary artery dis-
ease (CAD) in asymptomatic patients with type 2 diabetes.
Methods: Cohort study in 1080 asymptomatic patients with type 2 dia-
betes, a normal 12-lead resting electrocardiogram (ECG), at least one addi-
tional cardiovascular risk factor and low density lipoprotein (LDL) cholesterol
<3.4 mmol/L. Patients initially underwent screening for SMI by 201thallium
myocardial scintigraphy after an ECG stress test, a pharmacological stress test
(dipyridamole injection), or both. Patients with SMI underwent coronary angi-
ography.
Results: SMI was detected in 292 patients and CAD in 91 patients.
Overall, 60 (5.5%) patients had atherogenic dyslipidemia (triglycerides
≥2.04 g/l mmol/L and HDL cholesterol ≤0,34 g/l), which was associated with
SMI (40.0 vs 26.3%, p<0.001) and CAD (22.2 vs 8.3%, p<0.001). In multi-
variate analyses taking into account the parameters associated in univariate
analyses with SMI and then CAD, SMI was associated with atherogenic dys-
lipidemia (odds ratio 1.8[1.0-3.3]), male gender (OR 2.1[1.5-2.9]), BMI (OR
0.97[0.94-1.00]), retinopathy (OR 1.4[1.1-1.9]), peripheral occlusive arterial
disease (POAD: OR 2.5[1.6-3.8]) and mean blood pressure (OR 1.01[1.00-
1.03]); CAD was associated with atherogenic dyslipidemia (OR 4.0[1.7-9.2]),
male gender (OR 3.0[1.6-5.6]), BMI (OR 0.94[0.90-1.00]), retinopathy
(OR 1.7[1.0-2.9], POAD (OR 4.0[2.1-7.4]) and mean blood pressure
(OR 1.03[1.01-1.05]). In the subgroup of 584 patients at LDL cholesterol
<2.6 mmol/L, CAD was also independently associated with atherogenic dys-
lipidemia (2.96 [0.97-9.03], p=0.06).
Conclusions: In type 2 diabetic patients including those at LDL cholesterol
goal, atherogenic dyslipidemia is associated with an increased risk of silent
CAD. Management targeted to this dyslipidemic profile may help to reduce
the high residual burden of cardiovascular disease.
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There are evidences of a link between platelet reactivity inhibition and
thrombotic and bleeding events. We have previously demonstrated that PR
after prasugrel loading dose (LD) predicts short-term thrombotic events. We
aimed to further investigate the relationship between PR under prasugrel and
one-year thrombotic and bleeding events.
Method: Patients were prospectively included in this multicentre study if
they had a successful PCI for an acute coronary syndrome (ACS) and received
prasugrel. Vasodilator-Stimulated Phosphoprotein (VASP index) was mea-
sured after prasugrel LD. Endpoint included the rate of thrombotic events (car-
diovascular death, myocardial infarction and stent thrombosis) and bleeding
events (TIMI) at one year.
